FORA Capital LLC Makes New $2.99 Million Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

FORA Capital LLC bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 12,698 shares of the biopharmaceutical company's stock, valued at approximately $2,988,000.

Other large investors also recently modified their holdings of the company. Jennison Associates LLC acquired a new position in Alnylam Pharmaceuticals in the fourth quarter worth about $61,160,000. Strategic Financial Concepts LLC acquired a new position in Alnylam Pharmaceuticals in the fourth quarter worth about $41,529,000. Truist Financial Corp grew its stake in Alnylam Pharmaceuticals by 136.6% in the fourth quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company's stock worth $1,035,000 after purchasing an additional 2,539 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in Alnylam Pharmaceuticals by 3.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company's stock worth $67,464,000 after purchasing an additional 8,462 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in Alnylam Pharmaceuticals by 13.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company's stock worth $4,687,000 after purchasing an additional 2,285 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Yvonne Greenstreet sold 1,213 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $309,521.21. Following the sale, the chief executive officer now owns 81,526 shares of the company's stock, valued at $20,802,989.42. The trade was a 1.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the sale, the executive vice president now directly owns 12,881 shares in the company, valued at approximately $3,240,344.36. The trade was a 10.06% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 7,392 shares of company stock valued at $1,875,627 over the last quarter. Corporate insiders own 1.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ALNY. JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their price target for the stock from $280.00 to $328.00 in a research note on Monday, March 24th. Citigroup lifted their price target on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. William Blair reiterated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Chardan Capital lifted their price target on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Finally, StockNews.com raised shares of Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Thursday. One analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $319.17.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY traded down $6.35 during mid-day trading on Friday, reaching $252.00. 656,363 shares of the company's stock traded hands, compared to its average volume of 903,611. The business's 50-day moving average price is $250.53 and its 200-day moving average price is $253.70. The stock has a market capitalization of $32.86 billion, a P/E ratio of -116.13 and a beta of 0.17. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. Alnylam Pharmaceuticals, Inc. has a 12 month low of $144.73 and a 12 month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The firm had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. During the same quarter in the previous year, the business posted ($0.16) earnings per share. The company's revenue was up 20.2% on a year-over-year basis. Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.